Is EYLEA Approved for DME?: Understanding Its Role in Diabetic Macular Edema
•
2 min read
In July 2014, the U.S. Food and Drug Administration (FDA) first approved EYLEA (aflibercept) for the treatment of diabetic macular edema (DME). This pivotal approval, based on robust clinical trial data, established EYLEA as a standard of care for a significant complication of diabetic eye disease.
